NASDAQ:NKTX Nkarta Q4 2025 Earnings Results & Report $1.93 -0.10 (-4.93%) Closing price 10/15/2026 04:00 PM EasternExtended Trading$1.95 +0.02 (+1.04%) As of 10/15/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Nkarta missed analyst earnings expectations in its Q4 2025 results, released March 25, 2026. The company reported EPS of -$0.37 versus the -$0.32 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 25, 2026TimeBefore Market Opens Nkarta EPS ResultsActual EPS-$0.37Consensus EPS -$0.32Beat/MissMissed by -$0.05One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersNkarta Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsNkarta's Q3 2026 earnings is estimated for Tuesday, November 10, 2026, based on past reporting schedules, with a conference call scheduled on Monday, November 9, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Annual ReportSEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report Nkarta Q4 2025 Earnings FAQ Did Nkarta beat earnings estimates for Q4 2025? Nkarta (NASDAQ:NKTX) reported earnings of -$0.37 per share for Q4 2025, missing the consensus estimate of -$0.32. The report was announced on Wednesday, March 25, 2026. When is Nkarta's next earnings date? Nkarta's next earnings date is estimated for Tuesday, November 10, 2026. MarketBeat tracks confirmed and estimated earnings dates for Nkarta on the company's earnings history page. Nkarta Earnings HeadlinesH.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)September 24, 2026 | theglobeandmail.comNkarta to Participate in September Investor ConferencesSeptember 10, 2026 | globenewswire.comYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold. | American Alternative (Ad)Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026September 8, 2026 | globenewswire.comNkarta Reports Second Quarter 2026 Financial Results and Corporate HighlightsAugust 10, 2026 | markets.businessinsider.comNkarta Reports Continued Enrollment in Ntrust Autoimmune Trials and $243.2 Million Cash Position, Reaffirms Runway Into 2029August 10, 2026 | quiverquant.comQSee More Nkarta Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nkarta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nkarta and other key companies, straight to your email. Email Address About NkartaNkarta (NASDAQ:NKTX) (NASDAQ:NKTX) is a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies for cancer and autoimmune diseases. The company’s approach is designed to harness the innate immune activity of NK cells while using chimeric antigen receptors (CARs) to direct them toward specific disease-associated targets. Nkarta’s development platform includes allogeneic, or donor-derived, CAR NK cell therapies intended to be manufactured for use across multiple patients. Its pipeline has included NKX019, an anti-CD19 CAR NK therapy being investigated for diseases involving B cells, and NKX101, an NKG2D-based CAR NK therapy designed to recognize stress ligands expressed by certain cancer cells, including those associated with acute myeloid leukemia and other hematologic malignancies. Founded in 2015 and headquartered in South San Francisco, California, Nkarta conducts research and clinical development through collaborations with medical institutions and clinical-trial sites. The company’s programs remain investigational and have not been established as safe or effective for general use by regulatory authorities.View Nkarta ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
